Abstracts tagged "proteomics"

Abstract Number: 0650 • ACR Convergence 2022
The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis
Shudan Wang¹, Masako Suzuki², Daming Shao³, Muhammad Hamza Bukhari⁴, Brianna Lally⁵, Michael Belmont⁶, Jennifer Aguilan², Simone Sidoli², Anna Broder⁷ and J. Michelle Kahlenberg⁸, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴Norwalk Hospital/Yale University, Norkwalk, VA, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
Abstract Number: 0659 • ACR Convergence 2022
Comprehensive Proteomic Screen of Murine Lupus Serum and Cerebrospinal Fluid Uncovers Diagnostic and Therapeutic Targets
Joshua Reynolds¹, Chandra Mohan², Yaxi Li² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) through an unknown mechanism. Diagnosis currently relies on clinical criteria and…
Abstract Number: 0660 • ACR Convergence 2022
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Audrey Hagiwara¹, Moumita Bose¹, Aleksandr Stotland¹, Aleksandra Binek¹, Koen Raedschelders¹, Janet Wei¹, C. Noel Bairey Merz¹, Sarah Parker¹, Jennifer Van Eyk¹, Daniel Wallace¹, Mariko Ishimori² and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Health System, Los Angeles, CA
Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
Abstract Number: 0909 • ACR Convergence 2022
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Maria Luque-Tevar³, Pilar Font¹, Montserrat Romero-Gomez², Desiree Ruiz-Vilchez⁴, Sara Remuzgo-Martinez⁵, Raquel Lopez Mejias⁶, María Carmen Ábalos-Aguilera⁷, Rafaela Ortega-Castro¹, José Perez-Venegas⁸, Mª Dolores Ruiz-Montesinos⁸, Carmen Dominguez⁸, Carlos Rodriguez-Escalera⁹, Carmen Romero-Barco⁹, Antonio Fernandez-Nebro¹⁰, Natalia Mena Vazquez¹⁰, Jose Luis Marenco¹¹, Julia Uceda Montañez¹¹, Charo Santos¹², Nuria Barbarroja¹, Mª Angeles Aguirre¹³, Alejandro Escudero-Contreras², Eduardo Collantes¹, Miguel Ángel González-Gay¹⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³IMIBIC, Córdoba, Spain, ⁴Reina Sofia University Hospital, Cordoba, Cordoba, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶IDIVAL, Santander, Spain, ⁷Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁸Virgen Macarena University Hospital, Sevilla, Spain, ⁹Virgen de la Victoria Hospital, Málaga, Spain, ¹⁰Regional University Hospital of Málaga, Málaga, Spain, ¹¹Virgen de Valme University Hospital, Sevilla, Spain, ¹²Virgen de Valme University Hospital, Málaga, Spain, ¹³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
Abstract Number: 0975 • ACR Convergence 2022
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Paul Newcombe¹, Richard A. Furie², Yoshiya Tanaka³, Wendy White⁴, Dominic Sinibaldi⁴, Philip Brohawn⁴, Mark Lazarus¹, Nicola Ferrari¹, Raj Tummala⁴, Hussein Al-Mossawi¹, Andre Nogueria da Costa⁵, Daniel Muthas⁵ and Madhu Ramaswamy⁴, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…
Abstract Number: 1087 • ACR Convergence 2022
Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
Zachary Wallace¹, Amit Joshi¹, Xiaoqing Fu¹, Claire Cook¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with excess morbidity and mortality. Identifying novel biomarkers may reveal new therapeutic targets and clinically useful biomarkers of disease…
Abstract Number: 1127 • ACR Convergence 2022
Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
Chary Lopez-Pedrera¹, Rafaela Ortega-Castro¹, Tomás Cerdó², Pilar Font¹, María Martinez-Monllor³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², María Carmen Ábalos-Aguilera³, Nuria Barbarroja¹, Eduardo Collantes¹, María Ángeles Aguirre-Zamorano⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain
Background/Purpose: Systemic sclerosis (SSc) is an heterogeneous autoimmune disease. There is an unmet need of biomarkers for diagnosis, progression and therapeutic response.This study aimed to…
Abstract Number: 1129 • ACR Convergence 2022
Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy
Chary Lopez-Pedrera¹, Tomás Cerdó², María Ángeles Aguirre-Zamorano³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², Pilar Font¹, María Carmen Ábalos-Aguilera⁴, Pedro Ortiz-Buitrago⁴, Nuria Barbarroja¹, Eduardo Collantes¹, Rafaela Ortega-Castro¹ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. At present, our knowledge of serum protein patterns related to cardiovascular (CV) risk and…
Abstract Number: 1135 • ACR Convergence 2022
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, Anna Broder², Daming Shao³, Vartika Kesarwani⁴, Brianna Lally⁵, Masako Suzuki⁶, J. Michelle Kahlenberg⁷, Jennifer Aguilan⁶ and Simone Sidoli⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Hackensack University Medical Center, Hackensack, NJ, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴University of Connecticut, Farmington, CT, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
Abstract Number: 1163 • ACR Convergence 2022
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
Ji-Hyun Lee¹, Jeesoo Kim², Sang-Hyon kim¹, Jong‑Seo kim² and Chang-Nam son¹, ¹Keimyung University, Dalseo-gu, Daegu, Republic of Korea, ²seoul national university, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and peripheral joints, and the exact etiology is still unknown. Diagnosis…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 1176 • ACR Convergence 2022
Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier³, lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi³, David Launay³, Michel Salzet² and Vincent Sobanski³, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ⁴University of Lille, LILLE, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc).Recently, it has been shown that immunoglobulins G (IgG) from SSc promoted a proinflammatory and profibrotic phenotype…
Abstract Number: 0386 • ACR Convergence 2022
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
Mark Hwang¹, Jessica Castillo², kamala Vanarsa², Jim Zheng³, Shervin Assassi⁴, Chandra Mohan² and John Reveille⁵, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²University of Houston, Houston, TX, ³UTHealth School of Bioinformatics, Houston, TX, ⁴McGovern Medical School, University of Texas, Houston, TX, ⁵University of Texas McGovern Medical School, Houston, TX
Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
Abstract Number: 1537 • ACR Convergence 2022
Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis
Line Iversen¹, Ole Østergaard², Tina Friis³, susanne Ullman⁴, Søren Jacobsen⁵ and Jesper Olsen², ¹Department of Dermatology, Odense University Hospital., Odense, Denmark, ²Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, ³Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark
Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from…
Abstract Number: 0471 • ACR Convergence 2022
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Lisa Christ¹, Andrea Gloor², Florian Kollert¹, Timo Gaber³, Frank Buttgereit³, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].